Lemborexant: First Approval
Lesley J. Scott
10.6084/m9.figshare.11739492.v1
https://adisjournals.figshare.com/articles/online_resource/Lemborexant_First_Approval/11739492
<div><p><b>Compliance with Ethical Standards</b></p>
<p><b>Funding</b> The preparation of this review was not supported by any external funding.</p>
<b>Conflict
of interest<i> </i></b>During
the peer review process the manufacturer of the agent under review was offered
an opportunity to comment on the article. Changes resulting from any comments
received were made by the authors on the basis of scientific completeness and
accuracy. Lesley Scott is
a salaried employee of Adis International Ltd/Springer Nature, is responsible for
the article content and declares no relevant conflicts of interest.<br></div><div>Additional information about this Adis Drug Review can be found here<br></div><div><br></div><div><b>Abstract</b></div><div><p>Lemborexant
(DAYVIGO™) is an orally
administered, small molecule, competitive orexin receptor subtypes 1 and 2
antagonist is being developed by Eisai Inc. for the treatment of adult patients
with insomnia and for adults with irregular
sleep-wake rhythm disorder (ISWRD) associated with mild to moderate Alzheimer’s
disease. In December 2019, lemborexant received its first global
approval in the USA for the treatment of adult patients with insomnia,
characterized by difficulties with sleep onset and/or maintenance. This article
summarizes the milestones in the development of lemborexant leading to its
first global approval for the treatment of adult patients with insomnia,
characterized by difficulties with sleep onset and/or maintenance.</p></div><div><p>© Springer Nature Switzerland AG 2020</p></div><div><br></div>
2020-02-24 19:55:54
Lemborexant
Insomnia Disorder
Review
Adis Insight Report